Lycia Therapeutics Announces Pricing of Upsized Initial Public Offering
Lycia Therapeutics priced its upsized IPO at $18.00 per share, selling 17,640,000 shares for expected gross proceeds of approximately $317.5 million. The underwriters hold a 30-day option on up to 2,646,000 additional shares. Jefferies, TD Cowen, Evercore ISI and Guggenheim Securities are joint book-runners, with LifeSci Capital as passive book-runner. Shares are expected to begin trading on the Nasdaq Global Select Market on October 23 under the symbol LYCA, with closing expected October 26.
Key figures
- Deal Value Usd
- 317500000
- Offering Price
- 18
- Shares Offered
- 17640000
- Exchange
- Nasdaq Global Select Market
- Trading start
- 2026-10-23
- Expected close
- 2026-10-26
- Underwriter option days
- 30
- Underwriter option shares
- 2646000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.